Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2003 Jul;58(7):589–593. doi: 10.1136/thorax.58.7.589

Time course of recovery of health status following an infective exacerbation of chronic bronchitis

S Spencer 1, P Jones 1
PMCID: PMC1746751  PMID: 12832673

Abstract

Background: The magnitude and time course of effect of an acute exacerbation of chronic bronchitis (AECB) on health status are not known. Data from the GLOBE study, a randomised double blind trial of antibiotic therapy, were used to investigate these effects.

Methods: 438 patients with AECB received either gemifloxacin 320 mg once daily for 5 days (214 patients) or clarithromycin 500 mg twice daily for 7 days (224 patients) and were followed up for 26 weeks. St George's Respiratory Questionnaire (SGRQ) scores were obtained at baseline and after 4, 12, and 26 weeks.

Results: At presentation during an exacerbation SGRQ scores were worse (Total score difference 5.4 units, 95% CI 1.9 to 8.8, p=0.002) in patients who had a subsequent exacerbation during follow up. The greatest improvement in SGRQ score occurred within the first 4 weeks (mean 8.9 units, 95% CI 6.5 to 11.5, p<0.0001). Subsequently, scores improved more rapidly in patients with no further exacerbations. At 26 weeks the difference between the two groups was 9.6 units (95% CI 5.7 to 13.4, p<0.0001). In patients with no further exacerbations the SGRQ score improved between 4 and 12 weeks by a further 4.1 units (95% CI 2.2 to 5.9, p<0.0001).

Conclusions: A single infective AECB has a sustained effect on health status. The recovery period is long even in patients who have no further exacerbations. A second episode within 6 months limits recovery markedly. Treatments that reduce exacerbation frequency could have a significant impact on health status.

Full Text

The Full Text of this article is available as a PDF (144.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthonisen N. R., Manfreda J., Warren C. P., Hershfield E. S., Harding G. K., Nelson N. A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
  2. Ball P., Make B. Acute exacerbations of chronic bronchitis: an international comparison. Chest. 1998 Mar;113(3 Suppl):199S–204S. doi: 10.1378/chest.113.3_supplement.199s. [DOI] [PubMed] [Google Scholar]
  3. Donaldson G. C., Seemungal T. A. R., Bhowmik A., Wedzicha J. A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847–852. doi: 10.1136/thorax.57.10.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ferrer M., Villasante C., Alonso J., Sobradillo V., Gabriel R., Vilagut G., Masa J. F., Viejo J. L., Jiménez-Ruiz C. A., Miravitlles M. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J. 2002 Mar;19(3):405–413. doi: 10.1183/09031936.02.00213202. [DOI] [PubMed] [Google Scholar]
  5. Fujimura M., Myou S., Kamio Y., Ishiura Y., Iwasa K., Hashimoto T., Matsuda T. Increased airway responsiveness to acetaldehyde in asthmatic subjects with alcohol-induced bronchoconstriction. Eur Respir J. 1999 Jul;14(1):19–22. doi: 10.1034/j.1399-3003.1999.14a05.x. [DOI] [PubMed] [Google Scholar]
  6. Grossman R., Mukherjee J., Vaughan D., Eastwood C., Cook R., LaForge J., Lampron N. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. Chest. 1998 Jan;113(1):131–141. doi: 10.1378/chest.113.1.131. [DOI] [PubMed] [Google Scholar]
  7. Halpern Michael T., Palmer Cynthia S., Zodet Marc, Kirsch Jeff. Cost-effectiveness of gemifloxacin: results from the GLOBE study. Am J Health Syst Pharm. 2002 Jul 15;59(14):1357–1365. doi: 10.1093/ajhp/59.14.1357. [DOI] [PubMed] [Google Scholar]
  8. Jones P. W., Bosh T. K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997 Apr;155(4):1283–1289. doi: 10.1164/ajrccm.155.4.9105068. [DOI] [PubMed] [Google Scholar]
  9. Jones P. W. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001 Nov;56(11):880–887. doi: 10.1136/thorax.56.11.880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jones P. W. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002 Mar;19(3):398–404. doi: 10.1183/09031936.02.00063702. [DOI] [PubMed] [Google Scholar]
  11. Jones P. W., Quirk F. H., Baveystock C. M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321–1327. doi: 10.1164/ajrccm/145.6.1321. [DOI] [PubMed] [Google Scholar]
  12. Jones P. W., Willits L. R., Burge P. S., Calverley P. M. A., Inhaled Steroids in Obstructive Lung Disease in Europe study investigators Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003 Jan;21(1):68–73. doi: 10.1183/09031936.03.00013303. [DOI] [PubMed] [Google Scholar]
  13. Matthews J. N., Altman D. G., Campbell M. J., Royston P. Analysis of serial measurements in medical research. BMJ. 1990 Jan 27;300(6719):230–235. doi: 10.1136/bmj.300.6719.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Osman I. M., Godden D. J., Friend J. A., Legge J. S., Douglas J. G. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax. 1997 Jan;52(1):67–71. doi: 10.1136/thx.52.1.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schols A. M., Buurman W. A., Staal van den Brekel A. J., Dentener M. A., Wouters E. F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996 Aug;51(8):819–824. doi: 10.1136/thx.51.8.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Seemungal T. A., Donaldson G. C., Bhowmik A., Jeffries D. J., Wedzicha J. A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 May;161(5):1608–1613. doi: 10.1164/ajrccm.161.5.9908022. [DOI] [PubMed] [Google Scholar]
  17. Seemungal T. A., Donaldson G. C., Paul E. A., Bestall J. C., Jeffries D. J., Wedzicha J. A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418–1422. doi: 10.1164/ajrccm.157.5.9709032. [DOI] [PubMed] [Google Scholar]
  18. Spencer S., Calverley P. M., Sherwood Burge P., Jones P. W., ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Jan;163(1):122–128. doi: 10.1164/ajrccm.163.1.2005009. [DOI] [PubMed] [Google Scholar]
  19. Wilson C. B., Jones P. W., O'Leary C. J., Cole P. J., Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):536–541. doi: 10.1164/ajrccm.156.2.9607083. [DOI] [PubMed] [Google Scholar]
  20. Wilson Robert, Schentag Jerome J., Ball Peter, Mandell Lionel, 068 Study Group A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002 Apr;24(4):639–652. doi: 10.1016/s0149-2918(02)85139-6. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES